CD274 and neoplasm: Inhibition of the PD‐L1 pathway, by blocking of either the receptor or the ligand, has the potential to disinhibit cytotoxic T cells in the TME, resulting in long‐lasting antitumor activity in subsets of patients across tumor types [59, 60, 61, 62].